Can we select NSCLC patients for immune checkpoint therapy?

27 / 38

Age and ICI efficacy
84 72 341 353 425
0.2 1 2.5
75–84 yearsa
ITT
In favor of docetaxel Hazard Ratio
In favor of atezolizumab
OS HR
0.80 0.93
0.63 0.98
0.73 0.93
PFS HR
65–74 years
< 65 years
0.79 0.93
ORR (%) n (%)
453 (53%)
850 (100%)
307 (36%)
88 (10%)
13
14
14
13
14
15
8
17
0 10 20
Gadgeel – WCLC 2016
N Unstratified HR (95% CI)
<65 339 0.81 (0.62, 1.04)
≥65 and <75 200 0.63 (0.45, 0.89)
≥75 43 0.90 (0.43, 1.87)
OAK trial
Check Mate 057
Borghaei – NEJM 2015
KEYNOTE 010
Herbst – Lancet Oncol 2016